Toll Like Receptor 8 (CD288 or TLR8) - Pipeline Review, H2 2019
Toll Like Receptor 8 (CD288 or TLR8) - Pipeline Review, H2 2019
SUMMARY
Toll Like Receptor 8 (CD288 or TLR8) pipeline Target constitutes close to 22 molecules. Out of which approximately 21 molecules are developed by companies and remaining by the universities/institutes. The latest report Toll Like Receptor 8 (CD288 or TLR8) - Pipeline Review, H2 2019, outlays comprehensive information on the Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Toll Like Receptor 8 (CD288 or TLR8) - Toll-like receptor 8 is a protein encoded by the TLR8 gene. It control host immune response against pathogens through recognition of molecular patterns specific to microorganisms. Acts via MYD88 and TRAF6, leading to NF-kappa-B activation, cytokine secretion and the inflammatory response. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 6, 5, 8 and 2 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Immunology, Infectious Disease and Musculoskeletal Disorders which include indications Melanoma, Solid Tumor, Autoimmune Disorders, Head And Neck Cancer Squamous Cell Carcinoma, Metastatic Melanoma, Systemic Lupus Erythematosus, Adenoid Cystic Carcinoma (ACC), Arthritis, Colorectal Cancer, Cutaneous T-Cell Lymphoma, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Fibrosis, Hepatitis B, Hepatocellular Carcinoma, Inflammation, Leukemia, Medullary Thyroid Cancer, Merkel Cell Carcinoma, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Osteoarthritis, Peritoneal Cancer, Rabies, Renal Cell Carcinoma, Rheumatoid Arthritis, Sarcomas, Sicca Syndrome (Sjogren), Squamous Cell Carcinoma, Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) and Triple-Negative Breast Cancer (TNBC).
Furthermore, this report also reviews key players involved in Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
SCOPE
SUMMARY
Toll Like Receptor 8 (CD288 or TLR8) pipeline Target constitutes close to 22 molecules. Out of which approximately 21 molecules are developed by companies and remaining by the universities/institutes. The latest report Toll Like Receptor 8 (CD288 or TLR8) - Pipeline Review, H2 2019, outlays comprehensive information on the Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Toll Like Receptor 8 (CD288 or TLR8) - Toll-like receptor 8 is a protein encoded by the TLR8 gene. It control host immune response against pathogens through recognition of molecular patterns specific to microorganisms. Acts via MYD88 and TRAF6, leading to NF-kappa-B activation, cytokine secretion and the inflammatory response. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 6, 5, 8 and 2 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Immunology, Infectious Disease and Musculoskeletal Disorders which include indications Melanoma, Solid Tumor, Autoimmune Disorders, Head And Neck Cancer Squamous Cell Carcinoma, Metastatic Melanoma, Systemic Lupus Erythematosus, Adenoid Cystic Carcinoma (ACC), Arthritis, Colorectal Cancer, Cutaneous T-Cell Lymphoma, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Fibrosis, Hepatitis B, Hepatocellular Carcinoma, Inflammation, Leukemia, Medullary Thyroid Cancer, Merkel Cell Carcinoma, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Osteoarthritis, Peritoneal Cancer, Rabies, Renal Cell Carcinoma, Rheumatoid Arthritis, Sarcomas, Sicca Syndrome (Sjogren), Squamous Cell Carcinoma, Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) and Triple-Negative Breast Cancer (TNBC).
Furthermore, this report also reviews key players involved in Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Toll Like Receptor 8 (CD288 or TLR8)
- The report reviews Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics and enlists all their major and minor projects
- The report assesses Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Toll Like Receptor 8 (CD288 or TLR8)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Toll Like Receptor 8 (CD288 or TLR8) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Toll Like Receptor 8 (CD288 or TLR8) - Overview
Toll Like Receptor 8 (CD288 or TLR8) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Toll Like Receptor 8 (CD288 or TLR8) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Toll Like Receptor 8 (CD288 or TLR8) - Companies Involved in Therapeutics Development
Altimmune Inc
Ascendis Pharma A/S
BioNTech SE
Bolt Biotherapeutics Inc
Bristol-Myers Squibb Co
Curebiotech Inc
Curevac AG
Dynavax Technologies Corp
Eisai Co Ltd
Galderma SA
Gilead Sciences Inc
IngenoVax LLC
Janus Biotherapeutics Inc
Nektar Therapeutics
Resolve Therapeutics LLC
Seven and Eight Biopharmaceuticals Corp
Shanghai De Novo Pharmatech Co Ltd
Silverback Therapeutics Inc
Vaccex Inc
Toll Like Receptor 8 (CD288 or TLR8) - Drug Profiles
ALT-702 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BDB-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CUCPT-8m - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CV-8102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DN-1508052 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
E-6742 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INGMM-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JB-6121 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody Conjugates to Agonize TLR7 and TLR8 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
motolimod - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NKTR-262 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
resiquimod - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
resiquimod - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
resiquimod SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RSLV-132 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SBT-6050 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SC-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
selgantolimod - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize TLR7 and TLR8 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize TLR7 and TLR8 for Autoimmune Disorders and Inflammation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize TLR8 for Rheumatoid Arthritis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VTX-1463 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Toll Like Receptor 8 (CD288 or TLR8) - Dormant Products
Toll Like Receptor 8 (CD288 or TLR8) - Discontinued Products
Toll Like Receptor 8 (CD288 or TLR8) - Product Development Milestones
Featured News & Press Releases
Dec 12, 2019: Silverback Therapeutics announces preclinical data at 2019 San Antonio Breast Cancer Symposium (SABCS) supporting development of SBT6050 as a single agent and in combination with Trastuzumab for the treatment of HER2-expressing malignancies
Nov 09, 2019: Bolt Biotherapeutics presents preclinical data showing eradication of large resistant tumors with ISAC monotherapy at SITC 2019
Nov 06, 2019: Ascendis Pharma announces first presentation of preclinical data utilizing TransCon Technology in Oncology at SITC 2019
Nov 05, 2019: Silverback Therapeutics to Present Preclinical Data at SITC 34th Annual Meeting Demonstrating SBT6050’s Potential for Robust Single Agent Activity in Tumors Refractory to Checkpoint Inhibition
Nov 05, 2019: Bolt Biotherapeutics announces ISAC data presentation At the Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
Oct 24, 2019: CureVac to present CV8102 data at SITC Conference
Jul 22, 2019: Resolve Therapeutics announces completion of enrollment for phase 2a study of RSLV-132 for the treatment of lupus
Jul 02, 2019: Vaccex provides update on development of VX001
Jun 13, 2019: Resolve Therapeutics announces RSLV-132 significantly reduces fatigue in phase II study of patients with sjogrens syndrome
Jun 13, 2019: CureVac receives grants for three patents regarding intratumoral application of RNA
Jun 10, 2019: Resolve Therapeutics to Present Phase II Data on Lead Product Candidate RSLV-132 at the 2019 EULAR European Congress of Rheumatology
Jun 05, 2019: Altimmune announces important additions to its patent portfolio for ALT-702 Program
Apr 11, 2019: Gilead presents on its Hepatitis B drug candidate GS-9688 at the International Liver Congress 2019
Apr 01, 2019: Bolt Biotherapeutics presents preclinical proof of concept data at American Association for Cancer Research (AACR) Conference
Mar 21, 2019: CureVac announces late-breaking poster presentation at American Association of Cancer Research (AACR) Annual Meeting 2019
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Toll Like Receptor 8 (CD288 or TLR8) - Overview
Toll Like Receptor 8 (CD288 or TLR8) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Toll Like Receptor 8 (CD288 or TLR8) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Toll Like Receptor 8 (CD288 or TLR8) - Companies Involved in Therapeutics Development
Altimmune Inc
Ascendis Pharma A/S
BioNTech SE
Bolt Biotherapeutics Inc
Bristol-Myers Squibb Co
Curebiotech Inc
Curevac AG
Dynavax Technologies Corp
Eisai Co Ltd
Galderma SA
Gilead Sciences Inc
IngenoVax LLC
Janus Biotherapeutics Inc
Nektar Therapeutics
Resolve Therapeutics LLC
Seven and Eight Biopharmaceuticals Corp
Shanghai De Novo Pharmatech Co Ltd
Silverback Therapeutics Inc
Vaccex Inc
Toll Like Receptor 8 (CD288 or TLR8) - Drug Profiles
ALT-702 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BDB-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CUCPT-8m - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CV-8102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DN-1508052 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
E-6742 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INGMM-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JB-6121 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody Conjugates to Agonize TLR7 and TLR8 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
motolimod - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NKTR-262 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
resiquimod - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
resiquimod - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
resiquimod SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RSLV-132 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SBT-6050 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SC-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
selgantolimod - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize TLR7 and TLR8 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize TLR7 and TLR8 for Autoimmune Disorders and Inflammation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize TLR8 for Rheumatoid Arthritis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VTX-1463 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Toll Like Receptor 8 (CD288 or TLR8) - Dormant Products
Toll Like Receptor 8 (CD288 or TLR8) - Discontinued Products
Toll Like Receptor 8 (CD288 or TLR8) - Product Development Milestones
Featured News & Press Releases
Dec 12, 2019: Silverback Therapeutics announces preclinical data at 2019 San Antonio Breast Cancer Symposium (SABCS) supporting development of SBT6050 as a single agent and in combination with Trastuzumab for the treatment of HER2-expressing malignancies
Nov 09, 2019: Bolt Biotherapeutics presents preclinical data showing eradication of large resistant tumors with ISAC monotherapy at SITC 2019
Nov 06, 2019: Ascendis Pharma announces first presentation of preclinical data utilizing TransCon Technology in Oncology at SITC 2019
Nov 05, 2019: Silverback Therapeutics to Present Preclinical Data at SITC 34th Annual Meeting Demonstrating SBT6050’s Potential for Robust Single Agent Activity in Tumors Refractory to Checkpoint Inhibition
Nov 05, 2019: Bolt Biotherapeutics announces ISAC data presentation At the Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
Oct 24, 2019: CureVac to present CV8102 data at SITC Conference
Jul 22, 2019: Resolve Therapeutics announces completion of enrollment for phase 2a study of RSLV-132 for the treatment of lupus
Jul 02, 2019: Vaccex provides update on development of VX001
Jun 13, 2019: Resolve Therapeutics announces RSLV-132 significantly reduces fatigue in phase II study of patients with sjogrens syndrome
Jun 13, 2019: CureVac receives grants for three patents regarding intratumoral application of RNA
Jun 10, 2019: Resolve Therapeutics to Present Phase II Data on Lead Product Candidate RSLV-132 at the 2019 EULAR European Congress of Rheumatology
Jun 05, 2019: Altimmune announces important additions to its patent portfolio for ALT-702 Program
Apr 11, 2019: Gilead presents on its Hepatitis B drug candidate GS-9688 at the International Liver Congress 2019
Apr 01, 2019: Bolt Biotherapeutics presents preclinical proof of concept data at American Association for Cancer Research (AACR) Conference
Mar 21, 2019: CureVac announces late-breaking poster presentation at American Association of Cancer Research (AACR) Annual Meeting 2019
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Altimmune Inc, H2 2019
Pipeline by Ascendis Pharma A/S, H2 2019
Pipeline by BioNTech SE, H2 2019
Pipeline by Bolt Biotherapeutics Inc, H2 2019
Pipeline by Bristol-Myers Squibb Co, H2 2019
Pipeline by Curebiotech Inc, H2 2019
Pipeline by Curevac AG, H2 2019
Pipeline by Dynavax Technologies Corp, H2 2019
Pipeline by Eisai Co Ltd, H2 2019
Pipeline by Galderma SA, H2 2019
Pipeline by Gilead Sciences Inc, H2 2019
Pipeline by IngenoVax LLC, H2 2019
Pipeline by Janus Biotherapeutics Inc, H2 2019
Pipeline by Nektar Therapeutics, H2 2019
Pipeline by Resolve Therapeutics LLC, H2 2019
Pipeline by Seven and Eight Biopharmaceuticals Corp, H2 2019
Pipeline by Shanghai De Novo Pharmatech Co Ltd, H2 2019
Pipeline by Silverback Therapeutics Inc, H2 2019
Pipeline by Vaccex Inc, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Discontinued Products, H2 2019
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Altimmune Inc, H2 2019
Pipeline by Ascendis Pharma A/S, H2 2019
Pipeline by BioNTech SE, H2 2019
Pipeline by Bolt Biotherapeutics Inc, H2 2019
Pipeline by Bristol-Myers Squibb Co, H2 2019
Pipeline by Curebiotech Inc, H2 2019
Pipeline by Curevac AG, H2 2019
Pipeline by Dynavax Technologies Corp, H2 2019
Pipeline by Eisai Co Ltd, H2 2019
Pipeline by Galderma SA, H2 2019
Pipeline by Gilead Sciences Inc, H2 2019
Pipeline by IngenoVax LLC, H2 2019
Pipeline by Janus Biotherapeutics Inc, H2 2019
Pipeline by Nektar Therapeutics, H2 2019
Pipeline by Resolve Therapeutics LLC, H2 2019
Pipeline by Seven and Eight Biopharmaceuticals Corp, H2 2019
Pipeline by Shanghai De Novo Pharmatech Co Ltd, H2 2019
Pipeline by Silverback Therapeutics Inc, H2 2019
Pipeline by Vaccex Inc, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Discontinued Products, H2 2019
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
COMPANIES MENTIONED
Altimmune Inc
Ascendis Pharma A/S
BioNTech SE
Bolt Biotherapeutics Inc
Bristol-Myers Squibb Co
Curebiotech Inc
Curevac AG
Dynavax Technologies Corp
Eisai Co Ltd
Galderma SA
Gilead Sciences Inc
IngenoVax LLC
Janus Biotherapeutics Inc
Nektar Therapeutics
Resolve Therapeutics LLC
Seven and Eight Biopharmaceuticals Corp
Shanghai De Novo Pharmatech Co Ltd
Silverback Therapeutics Inc
Vaccex Inc
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
COMPANIES MENTIONED
Altimmune Inc
Ascendis Pharma A/S
BioNTech SE
Bolt Biotherapeutics Inc
Bristol-Myers Squibb Co
Curebiotech Inc
Curevac AG
Dynavax Technologies Corp
Eisai Co Ltd
Galderma SA
Gilead Sciences Inc
IngenoVax LLC
Janus Biotherapeutics Inc
Nektar Therapeutics
Resolve Therapeutics LLC
Seven and Eight Biopharmaceuticals Corp
Shanghai De Novo Pharmatech Co Ltd
Silverback Therapeutics Inc
Vaccex Inc
